Repligen Revenue Growth Rates (RGEN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Repligen Corp  (NASDAQ: RGEN)
 

RGEN's Revenue Growth by Quarter and Year

Repligen's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RGEN/growth
https://api.csimarket.com/api/v1/companies/RGEN/fundamentals
https://api.csimarket.com/api/v1/companies/RGEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RGEN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 209.31
2nd Quarter June 204.13
1st Quarter March 194.26
FY 607.70

RGENs Annual Revenue
Repligen's Revenue in the fiscal year 2025 $ 738.26 millions
Repligen's Revenue in the fiscal year 2024 $ 634.44 millions
Repligen's Revenue in the fiscal year 2023 $ 632.36 millions
Repligen's Revenue in the fiscal year 2022 $ 801.54 millions
Repligen's Revenue in the fiscal year 2021 $ 670.53 millions




RGEN Revenue third quarter 2026 Y/Y Growth Comment
Repligen Corp reported Revenue increase of 10.86% year on year in the third quarter 2026, to $ 209.31 millions, this is lower than Repligen Corp's recent average Revenue improvement of 29.36%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue growth. While Repligen Corp' s Revenue growth of 10.86% ranks overall at the positon no. 1525 in the third quarter 2026.


RGEN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.86 %
2nd Quarter June 11.93 %
1st Quarter March 14.83 %
FY   -

Financial Statements
Repligen's third quarter 2026 Revenue $ 209.31 millions RGEN's Income Statement
Repligen's third quarter 2025 Revenue $ 188.81 millions Quarterly RGEN's Income Statement


RGEN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.54 %
2nd Quarter June 5.08 %
1st Quarter March -1.84 %
FY (Year on Year)   -


Back to RGEN Growth rate Comparisons >> Back to RGEN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #255
Overall #1525

Revenue Y/Y Growth Statistics
High Average Low
162.58 % 29.36 % -29.66 %
(Dec 31 2021)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #255
Overall #1525
Revenue Y/Y Growth Statistics
High Average Low
162.58 % 29.36 % -29.66 %
(Dec 31 2021)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Repligen's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
78.99 % 6.8 % -18.28 %
(Mar 31 2012)  


RGEN's III. Quarter Q/Q Revenue Comment
Repligen Corp achieved in the III. Quarter 2026 below company average Revenue growth of 2.54% quarter on quarter, to $ 209.31 millions.

Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Repligen's Revenue growth quarter on quarter, overall rank is 1153.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #170
Overall #1153
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #170
Overall #1153
Revenue Q/Q Growth Statistics
High Average Low
78.99 % 6.8 % -18.28 %
(Mar 31 2012)  


RGEN's III. Quarter Q/Q Revenue Comment
Repligen Corp achieved in the III. Quarter 2026 below company average Revenue growth of 2.54% quarter on quarter, to $ 209.31 millions.

Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Repligen's Revenue growth quarter on quarter, overall rank is 1153.


Repligen's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 805.61
Y / Y Revenue Growth (TTM) 13.8 %
Year on Year Revenue Growth Overall Ranking # 1956
Seqeuential Revenue Change (TTM) 2.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 2205


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Repligen's cumulative twelve months Revenue were $ 806 millions, company would post below average annual Revenue growth of 2.61% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Repligen's Revenue growth from the 204.13% growth in Jun 30 2026.

In the Healthcare sector 295 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1313 to 1956.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 296
Overall # 1956

Revenue TTM Y/Y Growth Statistics
High Average Low
83.08 %
 25.02 %
-21.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 319
S&P 500 # 2205
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Repligen's cumulative twelve months Revenue were $ 806 millions, company would post below average annual Revenue growth of -21.11% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Repligen's Revenue growth from the 204.13% growth in Jun 30 2026.

In the Healthcare sector 295 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1313 to 1956.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 296
Overall # 1956

Revenue TTM Y/Y Growth Statistics
High Average Low
83.08 %
25.02 %
-21.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 319
S&P 500 # 2205




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RGEN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions


About Repligen Revenue Growth Rates (RGEN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Repligen Corp (CIK 730272).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-068562
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Repligen Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.